Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Intra-Cellular Ther (ITCI)

Intra-Cellular Ther (ITCI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,178,043
  • Shares Outstanding, K 105,575
  • Annual Sales, $ 464,370 K
  • Annual Income, $ -139,670 K
  • 60-Month Beta 1.01
  • Price/Sales 15.57
  • Price/Cash Flow N/A
  • Price/Book 11.06
Trade ITCI with:

Options Overview Details

View History
  • Implied Volatility 37.13% ( -1.04%)
  • Historical Volatility 35.87%
  • IV Percentile 7%
  • IV Rank 3.60%
  • IV High 115.58% on 04/15/24
  • IV Low 34.20% on 09/14/23
  • Put/Call Vol Ratio 0.05
  • Today's Volume 677
  • Volume Avg (30-Day) 803
  • Put/Call OI Ratio 1.19
  • Today's Open Interest 12,386
  • Open Int (30-Day) 15,575

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.19
  • Number of Estimates 6
  • High Estimate -0.12
  • Low Estimate -0.24
  • Prior Year -0.45
  • Growth Rate Est. (year over year) +57.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
66.26 +3.44%
on 07/01/24
78.53 -12.72%
on 06/18/24
+1.30 (+1.93%)
since 05/31/24
3-Month
64.09 +6.94%
on 05/20/24
84.89 -19.26%
on 04/16/24
+1.87 (+2.80%)
since 04/02/24
52-Week
45.50 +50.64%
on 10/30/23
84.89 -19.26%
on 04/16/24
+5.22 (+8.24%)
since 06/30/23

Most Recent Stories

More News
Intra-Cellular Therapies (NASDAQ: ITCI): A Comprehensive Analysis

Company Overview Intra-Cellular Therapies (NASDAQ: ITCI) is a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders. The company’s primary product...

ITCI : 68.54 (+0.81%)
Intra-Cellular: Q1 Earnings Snapshot

Intra-Cellular: Q1 Earnings Snapshot

ITCI : 68.54 (+0.81%)
UnitedHealth Group, Morgan Stanley rise; PNC Financial, Live Nation fall, Tuesday, 4/16/2024

Stocks that traded heavily or had substantial price changes on Tuesday: UnitedHealth Group, Morgan Stanley rise; PNC Financial, Live Nation fall

IP : 43.50 (+0.37%)
NTRS : 84.23 (+0.48%)
PNC : 158.84 (+1.73%)
ABX.TO : 22.71 (-0.48%)
LYV : 96.70 (+2.04%)
UNH : 498.24 (+0.73%)
ITCI : 68.54 (+0.81%)
MS : 99.65 (+0.49%)
Intra-Cellular: Q4 Earnings Snapshot

Intra-Cellular: Q4 Earnings Snapshot

ITCI : 68.54 (+0.81%)
Intra-Cellular: Q3 Earnings Snapshot

Intra-Cellular: Q3 Earnings Snapshot

ITCI : 68.54 (+0.81%)
Intra-Cellular: Q2 Earnings Snapshot

Intra-Cellular: Q2 Earnings Snapshot

ITCI : 68.54 (+0.81%)
Intra-Cellular: Q1 Earnings Snapshot

Intra-Cellular: Q1 Earnings Snapshot

ITCI : 68.54 (+0.81%)
Why Intra-Cellular Therapies Climbed Tuesday

The company's depression drug, Caplyta (lumateperone), did well in a phase 3 trial against two types of depression.

ITCI : 68.54 (+0.81%)
Biotech Sector Working Fast to Combat Alzheimer’s Disease Cases That are Set to Explode

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – March 15, 2023 – USA News Group  –  According to a 2022 study of more than 6 million patients 65 and older, the risk factor...

MRVL.VN : 0.120 (unch)
BIIB : 228.82 (-1.27%)
PRTA : 20.39 (-0.44%)
ITCI : 68.54 (+0.81%)
RHHBY : 34.4300 (-0.61%)
With Alzheimer’s Cases Set to Explode in the Near-Term, New Treatments and Diagnostics are Needed

USA News Group – According to a 2022 study of more than 6 million patients 65 and older, the risk factor for developing Alzheimer’s disease increases by 50-80% in older adults who caught COVID-19....

MRVL.VN : 0.120 (unch)
BIIB : 228.82 (-1.27%)
PRTA : 20.39 (-0.44%)
ITCI : 68.54 (+0.81%)
RHHBY : 34.4300 (-0.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular...

See More

Key Turning Points

3rd Resistance Point 70.44
2nd Resistance Point 69.91
1st Resistance Point 69.22
Last Price 68.54
1st Support Level 68.00
2nd Support Level 67.47
3rd Support Level 66.78

See More

52-Week High 84.89
Fibonacci 61.8% 69.84
Last Price 68.54
Fibonacci 50% 65.19
Fibonacci 38.2% 60.55
52-Week Low 45.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar